Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus chemotherapy after surgery for resectable HER2-positive gastric or gastroesophageal junction cancer
ChiCTR2000031168Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Disease-free survival. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2000031168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031168.